Kornimate/medical-research-clean huggingface dataset:
subcutaneous immunotherapy treatment for patients with hypersensitivity to parietaria judaica

Conditions: Allergic Rhinoconjunctivitis

Summary: the objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerized with glutaraldehyde) of the subcutaneous injection of parietaria judaica pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

immunotherapy is a specific treatment for allergic diseases. unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. this is a prospective double-blind placebo controlled study with two arms of treatment: placebo and active.

Eligibility criteria:
inclusion criteria: * informed consent, signed by the subject * positive clinical history of rhinitis/rhinoconjunctivitis allergy to parietaria pollen * patient of both gender aged from 18 up to 55 * diagnosed sensitivity to parietaria pollen base on: positive nasal provocation test positive prick test to p. judaica specific ige to p.judaica \>0,7ku/l - patients who are able to comply with the dose regime exclusion criteria: * relevant sensitivity to another perenne allergen * patient with asthma * use of immunotherapy during the last four years * treatment with b. blocking agents * patient suffering from some pathology in which adrenaline was contraindicated * subject suffers from a serious medical condition, which would interference the treatment and follow up of the subject in the study * subject suffers from autoimmune disease(thyroiditis, lupus, etc.) * conditions in which the patient can not offer full co-operation nad significant psychiatric disturbance. * intolerance to aspirin * pregnant women or with pregnancy risk and brest-feeding

Keywords: allergic, rhinoconjunctivitis, immunotherapy
drug-eluting balloon registry in routine clinical practice

Conditions: Coronary Artery Disease; Angioplasty, Balloon

Summary: the purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.


Eligibility criteria:
inclusion criteria: * after pre dilatation residual stenosis 30% and less and also without vessel dissection interrupted blood flow * age 20 and more * treated with balloon angioplasty * signed informed consent and agreed to follow protocol exclusion criteria: * allergy to paclitaxel, antiplatelet * history of side effect to heparin, aspirin, thienopyridines * history of bleeding tendency, coagulation disorder, blood transfusion reaction

Keywords: coronary artery disease angioplasty, balloon
recovering from covid-19

Conditions: SARS CoV 2 Infection

Summary: following the success of pilot data trialling a virtual community-based remote monitoring model, using bluetooth enabled pulse oximeters, which demonstrated a saving of 300 bed spaces over a three week period,9 a nationwide expansion is set to be implemented through nhs digital. participants who were on the virtual wards approximately 12 weeks after their admission and those referred to long-covid outpatient clinics will be approached. there is a particular lack of understanding as to whether post-covid syndrome constitutes a singular disease process. it has been suggested that the post-covid syndrome may be characterised into either an acute or chronic subtype, depending on whether symptoms extend beyond 12 weeks following initial diagnosis.7,10 however, it is not currently understood as to whether chronic post-covid is either an extension of acute post-covid or is a separate disease subtype that carries a distinct risk profile. however, there remains a paucity in the literature depicting the recovery experience, risk factors for the development of post-covid syndrome, management strategies, and qualitative experiences. this study aims to address these gaps


Eligibility criteria:
inclusion criteria * aged 18 years or over. * able to provide written consent. exclusion criteria * any participants that withdraw their consent. * any form of psychiatric disorder or a condition that, in the opinion of the investigator, may hinder communication with the research team. * inability to cooperate or communicate with the research team.

Keywords: monitoring, ambulatory vital signs remote monitoring
open prospective study for determination of predictive measures for pain during colonoscopy

Conditions: Pain

Summary: the aim of the study is to determine what precolonoscopic measures can be correlated to pain during colonoscopy

the aim of the work is to determine prdictive pre-endoscopic factors for pain during colonoscpy. these factors may be demographic, antrophometric, socio-ecomomic, related to previous medical staus or to anxiety levels. we will try to find an objective parameter for prdiction of pain during colonoscopy, so pre-procedural intervantion will be applied in order to reduce the pain.

Eligibility criteria:
inclusion criteria: * age 18-70 * screening colonoscopy exclusion criteria: * failed prior colonoscopy * pain as a main referral indication * complications during previous exam * inpatients * excision of more than 3 polyps * diagnosis ofcancer, ibd * incomplete exam

Keywords: colonoscopy pain rectal balloon
a study to assess the safety and preliminary efficacy of pt-523 in patients with advanced non-small cell lung cancer (nsclc)

Conditions: Non-Small-Cell Lung Carcinoma

Summary: this phase i/ii, multi-centered, non-randomized trial is designed to determine a safe dose of pt-523 for subjects, and to make preliminary evaluations on the activity of pt-523 as therapy in subjects with nsclc.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histologically or cytologically confirmed nsclc which is stage iii or stage iv, or recurrent disease, and failed therapy with a standard first line (phase i/ii) as well as second line chemotherapy regimen (phase i), or be intolerant of standard chemotherapy. receipt of one additional prior chemotherapy regimen for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant is allowable. a prior epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tk) antagonist is allowable (phase ii). * asymptomatic or treated brain metastases (including steroids) if last therapy was received \> 4 weeks from study entry and is deemed by the investigator to have a low likelihood of rapid deterioration. * ecog performance status 0 - 2. * adequate organ function and bone marrow reserve. * use of appropriate contraceptive method. * signed patient informed consent. exclusion criteria: * investigational agents within 30 days prior to day 1 of study. * known symptomatic or uncontrolled brain metastases. * uncontrolled intercurrent illness. * known human immunodeficiency virus (hiv), hepatitis a, b, c, d and e. * patient has uncontrolled pleural effusions. * patient has received nitrosoureas or mitomycin-c within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry.

Keywords: talotrexin pt-523 non-small cell lung carcinoma (nsclc)
effects of seaweed extract on blood glucose response to sucrose

Conditions: Glucose Intolerance; Diabetes Mellitus, Type 2; Healthy Diet; Postprandial Hyperglycemia

Summary: this study will examine the impact of the seaweed (ascophyllum nodosum) extract on blood glucose levels after a sugary drink in healthy subjects. the aim of this study is to investigate if the seaweed extract, when consumed with the sucrose, can lower blood glucose levels, compared to the raise after sucrose only, in healthy volunteers. the study is designed as an acute, double-blind, randomised, controlled crossover trial in 16 healthy subjects. participants will be asked to consume sucrose solution or sucrose solution with added seaweed extract.the effects on blood glucose levels will be determined over 2 hours after the consumption.

blood glucose levels after a meal rich in sugars depend, among other factors, on the activity of enzymes that digest sugar molecules to glucose. epidemiological studies suggest that glucose levels after a meal higher than normal, present a great risk for the onset of cardiovascular diseases. slowing the digestion of sugar through the inhibition of digestion enzymes have been demonstrated as a successful approach in preventing postprandial hyperglycaemia either with pharmacological agents (acarbose, miglitol) or natural dietary compounds. we demonstrated, in preclinical in vitro experiments, the unique potential of tested seaweed extract to inhibit rat sucrase. this study will examine the potential of the seaweed extract to modulate blood glucose levels after a sucrose drink in healthy subjects . the aim of this study is to investigate if the seaweed extract, when consumed with sucrose, can lower blood glucose levels, compared to the raise after sucrose only. the study is designed as an acute, double-blind, randomised, controlled crossover trial in 16 healthy subjects. participants will be asked to consume sucrose solution or sucrose solution with added seaweed extract.the effects on blood glucose levels (in capillary blood) will be determined over 2 hours after the consumption. all participants will be characterized for the activity of salivary a-amylase

Eligibility criteria:
inclusion criteria: * 18-60 years * healthy exclusion criteria: * smoking * diagnosis of any chronic illness (including diabetes, hypertension, gastrointestinal diseases etc.) * on long term prescribed medication (except contraceptives) * pregnant or lactating * on a special diet or dietary regimen (for weight management or if regularly consuming fruit extract supplements) * allergy to fruits vegetables, pollen or seaweed. * unwillingness to follow dietary recommendations or record the diet during recommended period * donated blood 4 weeks before or intend to donate blood during the study or 4 weeks after the last study samples * participation in another research project in parallel which also involves dietary intervention (e.g. taking vitamin supplements) or requires sampling of blood
car-t treatment for relapse / refractory type safety and effectiveness of lymphoma

Conditions: Lymphoma

Summary: the safety and feasibility of car-t cells (cd19.car-t) targeted at cd19 in the treatment of relapsed / refractory cd19 positive lymphoma were determined, and the proliferation and survival time of cd19.car-t cells in patients were determined.

the sponsors of this research also studied cd19.car-t cells for the treatment of leukemia and lymphoma, two courses of three transfusion 14 days after infection process standard training program , the safety and effectiveness have accumulated some of the data. in this study, the investigators will regenerate the cultured cells for 2 times in a course of treatment, and enter the patient's body . the investigators observed the safety and efficacy of car-t cell therapy.

Eligibility criteria:
inclusion criteria: 1. age is 16 years old, less than 70 years old, sex is not limited, race is not limited; 2. the pathological diagnosis was cd19 positive expression of b type lymphoma relapsed / refractory, meet any one of the following can be diagnosed with relapsed / refractory lymphoma: 1）the standard scheme of standardized treatment of more than 4 courses in 50%, or the condition of tumor size;2） standard treatment of cr, but the recurrence of use the original scheme or the current national consensus recommended second-line treatment can not get cr again;3） the relapse after haematopoietic stem cell transplantation; 3. the patient needs to have a lesion that can be used to detect or evaluate the disease. 4. 0\~1 score of physical status score of the eastern cancer cooperation group (ecog). 5. at the time of collection of peripheral white blood cell counts over 1 \* 10\^9/l; 6. expected survival time \> 90 days; 7. patients have the ability to know and sign informed consent. exclusion criteria: 1. pregnant or lactating women; 2. uncontrolled infection; 3. hiv infected people, hepatitis b or hcv active stage; 4. needs patients with long-term immunosuppressive therapy (such as allergies, autoimmune diseases, gvhd, etc.). 5. combined with active central nervous system malignant tumor invading; 6. has abnormal coagulation function, and there are patients with serious thrombus. 7. organ failure (appendix); a. heart: grade ii and above; b. liver: higher than grade ii; c. kidney: second stages of renal insufficiency and above; d. lung: the second grade was slightly hypofunction and above. e. brain: metastatic or active lesion of the central nervous system. 8. patients who participated in other clinical trials in the past 30 days or in other clinical trials; 9. researchers believe that patients are not suitable for the study.

Keywords: lymphoma car-t
sleep subtypes in adolescent depression

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to compare sleep neurophysiology and behavior in adolescents with mdd with hypersomnia (mdd-hyp) and insomnia (mdd-ins) with healthy controls (hc). in addition, the investigators will test the efficacy of a simple behavioral sleep restriction on mood and sleep in their sample.

the world health organization has identified depression as the leading cause of burden of disease amongst young people. subjective sleep complaints are often a core symptom of depression and highly prevalent with 60-90% of depressed adolescents suffering from disrupted sleep. this sleep disruption often takes the form of insomnia (e.g., difficulty falling or staying asleep, or waking too early) or hypersomnia (prolonged sleep episodes or excessive daytime sleepiness). the aim of the trial is to examine the efficacy of a simple behavioral sleep restriction two weeks in duration on mood and sleep in adolescents ages 14 to 17 years with and without major depressive disorder. during this period sleep is objectively measured using actigraphy and monitor mood using self-report. the results of the study will inform whether a simple behavioral sleep restriction beneficially impacts mood and sleep.

Eligibility criteria:
inclusion criteria: - this study will recruit adolescents (ages 14 to 17 years) with major depressive disorder (mdd) with insomnia (mdd-ins) and with hypersomnia (mdd-hyp) and age and gender matched controls (hc). inclusion criteria: key inclusion criteria for mdd hypersomnia group: * mdd as determined through the mini-kid * determination of hypersomnia as defined by excessive daytime sleepiness, or long sleep duration. * written informed consent key inclusion criteria for mdd insomnia group: * mdd as determined through the mini-kid * determination of insomnia as defined by the insomnia severity index * written informed consent exclusion criteria: * key exclusion criteria for all three groups include: * current or lifetime experience of frank psychosis or mania * presence of suicidal intent representing imminent risk as indicated during clinical interview * medical or neurological condition that could impact brain functioning * history of physical brain injury or blow to the head resulting in loss of consciousness greater than 5 minutes * do not meet criteria for substance or alcohol dependence in the last three months * presence of an organic sleep disorder (e.g., narcolepsy, sleep apnea) additional exclusion criteria for healthy control group: * presence of psychiatric disorder * self-reported disrupted, short or ill-timed sleep additional exclusion criteria for mdd-ins and mdd-hyp: • no sleep difficulties
preventing the progression of multiple sclerosis: early rehabilitative treatment and multimodal assessment - part b

Conditions: Multiple Sclerosis

Summary: it is widely recognized that physical exercise is safe and people with moderate multiple sclerosis (ms) are encouraged to train regularly to improve their skills in motor task execution. several studies demonstrated that these activities represent an effective low-cost therapy which leads to significant and clinically meaningful improvements in gait and balance in people with ms (pwms) with mild to moderate walking dysfunction, possibly also by promoting brain plasticity. there is general agreement within the scientific community on the importance of timing intervention also during the early stages of ms to preserve or improve walking and balance abilities and fostering brain functional adaptation, thus slowing down the disease progression. previous studies highlighted the need to early identify and manage gait disorders using a multimodal approach tailored on individual's need. moreover, functional near-infrared spectroscopy (fnirs) measures blood flow which accompanies neuronal activity and thus, it can provide spatial information about changes in cortical activation patterns due to the possible effects of exercise on cortical plasticity. to the best of the investigators knowledge, no published studies have assessed the effect of exercise on mobility and brain activity in pwms with minimal or clinically undetectable disability. this emphasizes the need of trials investigating the effect of walking exercise as preventive strategy on ms clinical worsening.


Eligibility criteria:
inclusion criteria: * age \> 17 years * stable disease course (without worsening over 1 point at the expanded disability status scale in the last 3 months) exclusion criteria: * major depression * mini-mental state examination \< 27 * other cardiovascular or orthopedic diseases that interfere with physical exercise * progressive course of the disease

Keywords: early phase non-disabled
study of ray1216 tablets compared with placebo in patients with mild to moderate covid-19

Conditions: Mild to Moderate COVID-19

Summary: this is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ray1216 tablets in the treatment of mild to moderate sars-cov-2 infection. the total study duration is up to 28 days.


Eligibility criteria:
inclusion criteria: 1. participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions. 2. participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures. 3. male or female participants aged 18-75 (including 18 and 75 years old). 4. confirmed sars-cov-2 infection 120 hours prior to randomization. 5. initial onset of covid-19 symptoms/signs within 48 hours before randomization. 6. fertile participants must agree to take effective contraceptive measures. exclusion criteria: 1. patients with severe or critical covid-19 who currently require hospitalization, or patients who are expected to develop into severe or critical disease and require hospitalization within 48h after randomization. 2. difficulty swallowing or a history of gastrointestinal diseases that seriously affect drug absorption. 3. active liver disease, or obvious abnormal liver function (alt or ast ≥ 3uln, or total bilirubin ≥ 2uln). 4. wbc \>1uln, or neu \<0.5ⅹ109/l. 5. receiving dialysis or have known moderate to severe renal impairment (egfr\<60ml/min/1.73m2). 6. other suspected or confirmed systemic infections. 7. current or expected use of strong cyp3a4 inducers, inhibitors or medications that are highly dependent on cyp3a4 or cyp2c19 for clearance. 8. prior or anticipated receipt of any vaccine within 28 days prior to enrollment and during study period. 9. use of antivirals against sars-cov-2 within 7 days prior to enrollment. 10. weight≤40kg. 11. pregnant, lactating women or those with a positive pregnancy test (sterilized or postmenopausal women may not have a pregnancy test). 12. previous administration with any investigational drug within 3 months before the study drug administration. 13. participants who are judged by the investigator to be unsuitable to participate in this study.
efficacy of tell-show-do behavior-management technique during local anesthesia in preschool children

Conditions: Dental Anxiety; Pain; Infant Behavior; Heart Rate and Rhythm Disorders

Summary: this will be a randomized, controlled, parallel-group clinical trial. the aim of this study will be to evaluate the effectiveness of "tell-show-do" behavior management technique versus a conventional technique (covering the patient's vision) during an inferior alveolar and lingual nerve block in preschool children referred for treatment at the school of dentistry, university of sao paulo, brazil. the sample will consist of 52 children from 3 years old to 5 years 11 months old who need dental pulp treatment and / or tooth extraction of primary molars. preschool children with no history of allergies to lidocaine anesthetic or systemic/neurological diseases and who did not take local anesthesia before the study will be include in this research.

children will be randomly allocated to treatment groups (n = 26 for each group) according to the technique: (1) tell-show-do and (2) conventional. anxiety and pain will be evaluated by the scale of facial image (eif) and wong-baker pain scale, respectively. the cooperation of the patient will be evaluated by behavioral scale frankl.

Eligibility criteria:
inclusion criteria: 1. preschool children with severe dental caries who need dental pulp treatment and / or tooth extraction of inferior primary molars. exclusion criteria: 1. preschool children with history of allergies to lidocaine (local anesthetic) 2. preschool children with systemic or neurological diseases 3. preschool children who have received local dental anaesthesia before this study

Keywords: pain infant behaviour heart rate dental anxiety
a randomized trial of 24-week versus 48-week courses of peginterferon plus ribavirin for hcv genotype-6 patients

Conditions: Chronic Hepatitis C

Summary: patients with hcv genotype 6 infection who have a rapid virological response to treatment are randomised to either 24 or 48 weeks hcv treatment. our hypothesis is that there is no important difference in effect between the two treatment effect.

high rate of infection of hepatitis c virus(hcv) genotype 6 was recently confirmed in southern china. recent study implied chronic hepatitis c genotype 6 responds better to the 48-week treatment with pegylated interferon and ribavirin than genotype 1. approximately 75.7% obtain sustained virological response (hcv rna undetectable 24 weeks after treatment) to this approach. however, the treatment is associated with many and sometimes serious side effects. in addition, the treatment is costly also in economical terms. shorter treatment for chronic hepatitis c genotype 6 is necessary to be assessed. in this randomised,open label,multicenter phase 3 trial with active controls patients are treated with pegylated interferon alfa 2a (180ug/week)and ribavirin(800-1200mg based on weight)for 4 weeks. those who are hcv rna negative at week 4 (\<50 iu; cobas amplicor monitor test, roche diagnostic) are defined as rapid virological responders and randomised to either an additional 20 or 44 weeks combination treatment. patients who are hcv rna positive are all treated for 44 more weeks. the endpoint is sustained virological response defined as undetectable hcv rna 24 weeks after end of treatment. our hypothesis is that there is no important difference in the effect in the two groups. this is a non-inferiority trial. the smallest difference considered to be clinically important is 15%. thus to state "non-inferiority" the 95% confidence interval of the observed difference between the groups shall not overlap 10%. both intention to treat and and per protocol analyses will be published. conclusion will be conservative and based on the analysis who detect the biggest difference.

Eligibility criteria:
inclusion criteria: * hcv rna is positive * genotype 6 * treatment naive * raised alt exclusion criteria: * active substance abuse * poorly controlled psychiatric disease * hbsag positive * anti-hiv positive * suffering from other significant concurrent medical conditions including chronic liver diseases